企業プロフィール
Sagimet Biosciences 株価・ニュース・カタリスト
- ティッカー:
- SGMT
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
10.43 USD (-1.14%)
終値
最終更新: 2026年8月17日
419M USD
時価総額
株価変動の要因
The latest monitored company update is “Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
企業概要
Metabolic Pathway Therapeutics
Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production.
Denifanstat
Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology.
Dermatology Focus
Sagimet is prioritizing moderate-to-severe acne, where reduced sebaceous lipid synthesis may address an upstream disease mechanism.
今後のカタリスト
- A U.S. Phase 3 study of denifanstat in moderate-to-severe acne is planned to begin in the second half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。